Nanozyme-Enabled Treatment of Cardio- and Cerebrovascular Diseases

IF 13 2区材料科学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Small Pub Date : 2022-10-03 DOI:10.1002/smll.202204809

Yihong Zhang, Wanling Liu, Xiaoyu Wang, Yufeng Liu, Hui Wei

{"title":"Nanozyme-Enabled Treatment of Cardio- and Cerebrovascular Diseases","authors":"Yihong Zhang, Wanling Liu, Xiaoyu Wang, Yufeng Liu, Hui Wei","doi":"10.1002/smll.202204809","DOIUrl":null,"url":null,"abstract":"<p>Cardio- and cerebrovascular diseases are two major vascular-related diseases that lead to death worldwide. Reactive oxygen species (ROS) play a vital role in the occurrence and exacerbation of diseases. Excessive ROS induce cellular context damage and lead to tissue dysfunction. Nanozymes, as emerging enzyme mimics, offer a unique perspective for therapy through multifunctional activities, achieving essential results in the treatment of ROS-related cardio- and cerebrovascular diseases by directly scavenging excess ROS or regulating pathologically related molecules. This review first introduces nanozyme-enabled therapeutic mechanisms at the cellular level. Then, the therapies for several typical cardio- and cerebrovascular diseases with nanozymes are discussed, mainly including cardiovascular diseases, ischemia reperfusion injury, and neurological disorders. Finally, the challenges and outlooks for the application of nanozymes are also presented. This review will provide some instructive perspectives on nanozymes and promote the development of enzyme-mimicking strategies in cardio- and cerebrovascular disease therapy.</p>","PeriodicalId":228,"journal":{"name":"Small","volume":"19 13","pages":""},"PeriodicalIF":13.0000,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Small","FirstCategoryId":"88","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/smll.202204809","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 13

Abstract

Cardio- and cerebrovascular diseases are two major vascular-related diseases that lead to death worldwide. Reactive oxygen species (ROS) play a vital role in the occurrence and exacerbation of diseases. Excessive ROS induce cellular context damage and lead to tissue dysfunction. Nanozymes, as emerging enzyme mimics, offer a unique perspective for therapy through multifunctional activities, achieving essential results in the treatment of ROS-related cardio- and cerebrovascular diseases by directly scavenging excess ROS or regulating pathologically related molecules. This review first introduces nanozyme-enabled therapeutic mechanisms at the cellular level. Then, the therapies for several typical cardio- and cerebrovascular diseases with nanozymes are discussed, mainly including cardiovascular diseases, ischemia reperfusion injury, and neurological disorders. Finally, the challenges and outlooks for the application of nanozymes are also presented. This review will provide some instructive perspectives on nanozymes and promote the development of enzyme-mimicking strategies in cardio- and cerebrovascular disease therapy.

Abstract Image

查看原文本刊更多论文

纳米酶治疗心脑血管疾病

心脑血管疾病是世界范围内导致死亡的两种主要血管相关疾病。活性氧(Reactive oxygen species, ROS)在疾病的发生和恶化中起着至关重要的作用。过量的活性氧诱导细胞环境损伤，导致组织功能障碍。纳米酶作为新兴的酶模拟物，通过多功能活动为治疗提供了独特的视角，通过直接清除过量的ROS或调节病理相关分子，在ROS相关的心脑血管疾病的治疗中取得了重要的效果。本文首先介绍了纳米酶在细胞水平上的治疗机制。然后，讨论了纳米酶治疗几种典型的心脑血管疾病，主要包括心血管疾病、缺血再灌注损伤和神经系统疾病。最后，对纳米酶的应用面临的挑战和前景进行了展望。本文将为纳米酶的研究提供一些有指导意义的观点，并促进酶模拟技术在心脑血管疾病治疗中的发展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Small 工程技术-材料科学：综合

CiteScore

17.70

自引率

3.80%

发文量

1830

审稿时长

2.1 months

期刊介绍： Small serves as an exceptional platform for both experimental and theoretical studies in fundamental and applied interdisciplinary research at the nano- and microscale. The journal offers a compelling mix of peer-reviewed Research Articles, Reviews, Perspectives, and Comments. With a remarkable 2022 Journal Impact Factor of 13.3 (Journal Citation Reports from Clarivate Analytics, 2023), Small remains among the top multidisciplinary journals, covering a wide range of topics at the interface of materials science, chemistry, physics, engineering, medicine, and biology. Small's readership includes biochemists, biologists, biomedical scientists, chemists, engineers, information technologists, materials scientists, physicists, and theoreticians alike.